Us was Pharming’s largest revenue line in fiscal 2025, bringing in $311.67M of $319.77M (97%).
| Products and services [axis] | FY 2018 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|
| Us | $200.08M | $221.20M | $246.60M | $311.67M | ||
| Europe | — | — | — | — | ||
| Europe & Row | $5.54M | $5.90M | $5.59M | $8.10M | ||
| Row | — | — | — | — | ||
| Total | $205.62M | $227.10M | $252.19M | $319.77M |
Pharming brought in $319.77M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. That is less than the $361.75M it reports by products and services, so these revenue lines do not cover all of its revenue. Us was the largest at $311.67M (97.5%), ahead of Europe & Row at $8.10M (2.5%).
Compared with fiscal 2024, Europe & Row grew 44.9% to $8.10M and Us grew 26.4% to $311.67M.
Ruconest was Pharming’s largest revenue line in fiscal 2025, bringing in $311.67M of $361.75M (86%).
| Products And Services | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Ruconest | $200.08M | $221.20M | $246.60M | $311.67M | |
| Joenja | — | $17.89M | $40.50M | $50.07M | |
| Total | $200.08M | $239.09M | $287.10M | $361.75M |
Pharming brought in $361.75M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. That was up 26.0% from $287.10M in fiscal 2024. Ruconest was the largest at $311.67M (86.2%), ahead of Joenja at $50.07M (13.8%).
Compared with fiscal 2024, Ruconest grew 26.4% to $311.67M and Joenja grew 23.6% to $50.07M.
Pharming began breaking out Joenja in fiscal 2023, when it brought in $17.89M.
Pharming (PHAR) reports its revenue by products and services [axis] and by products and services. In fiscal 2025, Us was its largest revenue line, bringing in $311.67M (97.5% of the total), followed by Europe & Row at $8.10M (2.5%).
Us was Pharming's largest revenue line in fiscal 2025, bringing in $311.67M, or 97.5% of the $319.77M total across its two revenue lines.
Europe & Row grew faster than Us in fiscal 2025, up 44.9% from $5.59M to $8.10M. Us grew 26.4% to $311.67M.
Every figure comes from Pharming's annual financial filings, as reported. Each line keeps the name Pharming gives it, and years follow its fiscal calendar.
Pharming's revenue by products and services [axis] goes back to fiscal 2018, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.